Action Potential Venture Capital Ltd.

What is Action Potential Venture Capital Ltd.?

Action Potential Venture Capital Ltd. (APVC) is a leading medical technology venture capital firm with a specific focus on the development and innovation of bioelectronic medicines. Founded by GSK in 2013 and headquartered on One Broadway, 4th Floor, Cambridge, Massachusetts, APVC operates with a commitment to nurturing breakthroughs in healthcare. They manage assets amounting to $50 million and are active in seed, startup, early stage, expansion, and later stage investments, providing not just funding but also strategic support to entrepreneurs and innovators.

Bioelectronic medicines are at the core of APVC's interest, which are an emerging therapeutic field that harnesses the convergence of hardware, computing, and material science to manipulate neural or cellular activity, thereby offering new treatments for chronic diseases. The firm takes a hands-on approach, often involving itself directly on the boards of startups that advance bioelectronic medicines and associated enabling technologies.

APVC's investment thesis hinges on the belief that electrical, electromagnetic, and acoustic energy can be utilized to modulate the nervous system, which in turn plays a pivotal role in controlling various organs and bodily functions. The venture capital firm emphasizes the significance of having an inclusive and diverse workspace and holds their investments to the same standard of promoting equity within the healthcare investor and entrepreneurial community.

APVC's team is engaged internationally, looking to back the next generation of pioneers on the journey towards a bioelectronic future and a more equitable healthcare landscape.